Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: Predicting in vivo potency

被引:37
作者
Aston, Philip J. [1 ]
Derks, Gianne [1 ]
Raji, Adewale [1 ,2 ,3 ]
Agoram, Balaji M. [2 ]
van der Graaf, Piet H. [2 ]
机构
[1] Univ Surrey, Dept Math, Guildford GU2 7XH, Surrey, England
[2] Pfizer, PDM, Clin Pharmacol & Pharmacometr, Sandwich CT13 9NJ, Kent, England
[3] Univ Reading, Knowledge Transfer Ctr, Reading RG6 6AH, Berks, England
关键词
Pharmacology; Efficacy; Affinity; Target-mediated drug disposition; IgE; MEDIATED DRUG DISPOSITION; QUANTITATIVE PHARMACOLOGY; MODEL; BIOLOGICS;
D O I
10.1016/j.jtbi.2011.04.030
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We consider the relationship between the target affinity of a monoclonal antibody and its in vivo potency. The dynamics of the system is described mathematically by a target-mediated drug disposition model. As a measure of potency, we consider the minimum level of the free receptor following a single bolus injection of the ligand into the plasma compartment. From the differential equations, we derive two expressions for this minimum level in terms of the parameters of the problem, one of which is valid over the full range of values of the equilibrium dissociation constant K(D) and the other which is valid only for a large drug dose or for a small value of K(D). Both of these formulae show that the potency achieved by increasing the association constant k(on) can be very different from the potency achieved by decreasing the dissociation constant k(off). In particular, there is a saturation effect when decreasing koff where the increase in potency that can be achieved is limited, whereas there is no such effect when increasing k(on). Thus, for certain monoclonal antibodies, an increase in potency may be better achieved by increasing Icon than by decreasing koff. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:113 / 121
页数:9
相关论文
共 21 条
[1]   Type I Interferon Receptor is a Primary Regulator of Target-Mediated Drug Disposition of Interferon-β in Mice [J].
Abraham, Anson K. ;
Kagan, Leonid ;
Kumar, Sarmishtha ;
Mager, Donald E. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (01) :327-332
[2]   The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics [J].
Agoram, Balaji M. ;
Martin, Steven W. ;
van der Graaf, Piet H. .
DRUG DISCOVERY TODAY, 2007, 12 (23-24) :1018-1024
[3]   Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics [J].
Agoram, Balaji M. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (02) :153-160
[4]   Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets [J].
Davda, Jasmine P. ;
Hansen, Ryan J. .
MABS, 2010, 2 (05) :576-588
[5]   Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies [J].
De Genst, E ;
Silence, K ;
Decanniere, K ;
Conrath, K ;
Loris, R ;
Kinne, R ;
Muyldermans, S ;
Wyns, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (12) :4586-4591
[6]   Engineered CH2 domains (nanoantibodies) [J].
Dimitrov, Dimiter S. .
MABS, 2009, 1 (01) :26-28
[7]  
Gabrielsson J., 2006, PHARMACOKINETIC PHAR
[8]   Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics [J].
Gibiansky, Leonid ;
Gibiansky, Ekaterina .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (07) :803-812
[9]   A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab [J].
Hayashi, Naoto ;
Tsukamoto, Yuko ;
Sallas, William M. ;
Lowe, Philip J. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (05) :548-561
[10]   Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis [J].
Krippendorff, Ben-Fillippo ;
Kuester, Katharina ;
Kloft, Charlotte ;
Huisinga, Wilhelm .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2009, 36 (03) :239-260